NICE - Endorsed Technology Appraisals 2012/2013
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisal Endorsement Process
The following technology appraisals were endorsed during 2012-13 using the process that came into effect on 28 September 2011. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2013
- TA 275 - Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
- TA 274 - Ranibizumab for treating diabetic macularoedema (rapid review of technologyappraisal guidance 237)
February 2013
- TA 272 - Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
- TA 271 - Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema
- TA 265 - Denosumab for the treatment of bone metastases from solid tumours
January 2013
- TA 269- Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive melanoma
- TA 268 - Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma
December 2012
- TA 267 - Ivabradine for the treatment of chronic heart failure
- TA 266 - Mannitol dry powder for inhalation for the treatment of cystic fibrosis
October 2012
- TA 264 - Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122)
September 2012
August 2012
July 2012
- TA 260 - Botulinum toxin type A for the prophylaxis of headaches associated with chronic migraine
- TA 259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
- TA 258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
- TA 257 - Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic - hormone receptor positive breast cancer which over-expresses HER2
June 2012
May 2012
- TA 255 - Cabazitaxel for the second line treatment of hormone refractory, metastatic prostate cancer
- This guidance has been updated and replaced by TA 391 - Cabazitaxel for hormone relapsed metastatic prostate cancer treated with docetaxel, which was endorsed by the DoH in June 2016.
- TA 254 - Fingolimod for the treatment of relapsing-remitting multiple sclerosis
- TA 253 - Boceprevir for the treatment of genotype 1 chronic hepatitis C
- This Guidance has been Withdrawn
- TA 252 - Telaprevir for the treatment of genotype 1 chronic hepatitis C
- This Guidance has been Withdrawn
- TA 251 - Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (incl part-review of TA 70)
- This guidance has been updated and replaced by TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia, which was endorsed by the DoH in January 2017.
- TA 250 - Eribulin for the treatment of locally advanced or metastatic breast cancer
- This guidance has been updated and replaced by TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens, which was endorsed by the DoH in January 2017.
- This guidance has been updated and replaced by TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen, which was endorsed by the DoH in April 2018.
April 2012
Endorsed With Caveats
None
Not Endorsed as Applicable to Northern Ireland
None